{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:24:36Z","timestamp":1787099076434,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03233-w","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:04:59Z","timestamp":1781255099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Apolipoprotein B100 predicts cardiovascular and limb events in type 2 diabetes patients with chronic limb-threatening ischemia"],"prefix":"10.1186","volume":"25","author":[{"given":"Federico","family":"Biscetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Margherita","family":"Rando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Anna","family":"Nicolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis H.","family":"Eraso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Dimuzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Pitocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Flex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"3233_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01123-3","volume":"19","author":"F Biscetti","year":"2020","unstructured":"Biscetti F, Nardella E, Rando MM, Cecchini AL, Bonadia N, Bruno P, et al. Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study. Cardiovasc Diabetol. 2020;19:147. https:\/\/doi.org\/10.1186\/s12933-020-01123-3.","journal-title":"Cardiovasc Diabetol"},{"key":"3233_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12933-020-01151-z","volume":"19","author":"F Biscetti","year":"2020","unstructured":"Biscetti F, Nardella E, Rando MM, Cecchini AL, Angelini F, Cina A, et al. Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study. Cardiovasc Diabetol. 2020;19:170. https:\/\/doi.org\/10.1186\/s12933-020-01151-z.","journal-title":"Cardiovasc Diabetol"},{"key":"3233_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","volume":"67","author":"J Nordanstig","year":"2024","unstructured":"Nordanstig J, Behrendt C-A, Baumgartner I, Belch J, B\u00e4ck M, Fitridge R, et al. Editor\u2019s choice\u2014European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication. Eur J Vasc Endovasc Surg. 2024;67:9\u201396. https:\/\/doi.org\/10.1016\/j.ejvs.2023.08.067.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"3233_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78576-z","volume":"14","author":"F Biscetti","year":"2024","unstructured":"Biscetti F, Rando MM, Nicolazzi MA, Rossini E, Santoro M, Angelini F, et al. Evaluation of sirtuin 1 as a predictor of cardiovascular outcomes in diabetic patients with limb-threatening ischemia. Sci Rep. 2024;14:26940. https:\/\/doi.org\/10.1038\/s41598-024-78576-z.","journal-title":"Sci Rep"},{"key":"3233_CR5","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). Eur Heart J. 2024;45:3538\u2013700. https:\/\/doi.org\/10.1093\/eurheartj\/ehae179.","journal-title":"Eur Heart J"},{"issue":"46","key":"3233_CR6","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"2025","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2025;2025(46):4359\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"key":"3233_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042002","volume":"22","author":"F Biscetti","year":"2021","unstructured":"Biscetti F, Nardella E, Rando MM, Cecchini AL, Gasbarrini A, Massetti M, et al. Outcomes of lower extremity endovascular revascularization: potential predictors and prevention strategies. Int J Mol Sci. 2021;22:2002. https:\/\/doi.org\/10.3390\/ijms22042002.","journal-title":"Int J Mol Sci"},{"key":"3233_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.athplu.2021.10.003","volume":"46","author":"F Biscetti","year":"2021","unstructured":"Biscetti F, Cecchini AL, Rando MM, Nardella E, Gasbarrini A, Massetti M, et al. Principal predictors of major adverse limb events in diabetic peripheral artery disease: a narrative review. Atheroscler Plus. 2021;46:1\u201314. https:\/\/doi.org\/10.1016\/j.athplu.2021.10.003.","journal-title":"Atheroscler Plus"},{"key":"3233_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14020123","author":"D Kounatidis","year":"2024","unstructured":"Kounatidis D, Vallianou NG, Poulaki A, Evangelopoulos A, Panagopoulos F, Stratigou T, et al. ApoB100 and atherosclerosis: What\u2019s new in the 21st century? Metabolites. 2024. https:\/\/doi.org\/10.3390\/metabo14020123.","journal-title":"Metabolites"},{"key":"3233_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106873","volume":"195","author":"F Galimberti","year":"2023","unstructured":"Galimberti F, Casula M, Olmastroni E. Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment. Pharmacol Res. 2023;195:106873. https:\/\/doi.org\/10.1016\/j.phrs.2023.106873.","journal-title":"Pharmacol Res"},{"key":"3233_CR11","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e48-60. https:\/\/doi.org\/10.1161\/ATV.0000000000000147.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3233_CR12","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jacl.2025.04.204","volume":"19","author":"S Funabashi","year":"2025","unstructured":"Funabashi S, Kataoka Y, Nicholls SJ, Kitahara S, Makino H, Matsubara M, et al. Circulating apolipoprotein B levels in statin-treated type 2 diabetic patients with coronary artery disease: implications for coronary atheroma progression and instability. J Clin Lipidol. 2025;19:888\u201398. https:\/\/doi.org\/10.1016\/j.jacl.2025.04.204.","journal-title":"J Clin Lipidol"},{"key":"3233_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5551\/jat.RV17023","volume":"25","author":"T Hirano","year":"2018","unstructured":"Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25:771\u201382. https:\/\/doi.org\/10.5551\/jat.RV17023.","journal-title":"J Atheroscler Thromb"},{"key":"3233_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02307-6","volume":"23","author":"MB Rehman","year":"2024","unstructured":"Rehman MB, Tudrej BV. Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk. Lipids Health Dis. 2024;23:316. https:\/\/doi.org\/10.1186\/s12944-024-02307-6.","journal-title":"Lipids Health Dis"},{"key":"3233_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41:255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"key":"3233_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","volume":"58","author":"MS Conte","year":"2019","unstructured":"Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58:S1-S109.e33. https:\/\/doi.org\/10.1016\/j.ejvs.2019.05.006.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"3233_CR17","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/bmj.285.6346.916","volume":"285","author":"DJ Ewing","year":"1982","unstructured":"Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed). 1982;285:916\u20138. https:\/\/doi.org\/10.1136\/bmj.285.6346.916.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"3233_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"3233_CR19","doi-asserted-by":"publisher","first-page":"S395","DOI":"10.1097\/01.rvi.0000094613.61428.a9","volume":"14","author":"D Sacks","year":"2003","unstructured":"Sacks D, Marinelli DL, Martin LG, Spies JB, Society of Interventional Radiology Technology Assessment Committee. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. J Vasc Interv Radiol. 2003;14:S395-404. https:\/\/doi.org\/10.1097\/01.rvi.0000094613.61428.a9.","journal-title":"J Vasc Interv Radiol"},{"key":"3233_CR20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1709118.","journal-title":"N Engl J Med"},{"key":"3233_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with Evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137:338\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032235.","journal-title":"Circulation"},{"key":"3233_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"key":"3233_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02833-2","volume":"24","author":"F Biscetti","year":"2025","unstructured":"Biscetti F, Rando MM, Nicolazzi MA, Angelini F, Iezzi R, Eraso LH, et al. Prognostic value of lipoprotein(a) for cardiovascular events after lower limb revascularization in diabetic patients with chronic limb-threatening ischemia. Cardiovasc Diabetol. 2025;24:271. https:\/\/doi.org\/10.1186\/s12933-025-02833-2.","journal-title":"Cardiovasc Diabetol"},{"key":"3233_CR24","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287\u201395. https:\/\/doi.org\/10.1001\/jamacardio.2019.3780.","journal-title":"JAMA Cardiol"},{"key":"3233_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","volume":"150","author":"D De Oliveira-Gomes","year":"2024","unstructured":"De Oliveira-Gomes D, Joshi PH, Peterson ED, Rohatgi A, Khera A, Navar AM. APOLIPOPROTEIN B: bridging the gap between evidence and clinical practice. Circulation. 2024;150:62\u201379. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.068885.","journal-title":"Circulation"},{"key":"3233_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","volume":"21","author":"S Tsimikas","year":"2024","unstructured":"Tsimikas S, Witztum JL. Oxidized phospholipids in cardiovascular disease. Nat Rev Cardiol. 2024;21:170\u201391. https:\/\/doi.org\/10.1038\/s41569-023-00937-4.","journal-title":"Nat Rev Cardiol"},{"key":"3233_CR27","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2337\/dc19-0408","volume":"42","author":"F Biscetti","year":"2019","unstructured":"Biscetti F, Ferraro PM, Hiatt WR, Angelini F, Nardella E, Cecchini AL, et al. Inflammatory cytokines associated with failure of lower-extremity endovascular revascularization (LER): a prospective study of a population with diabetes. Diabetes Care. 2019;42:1939\u201345. https:\/\/doi.org\/10.2337\/dc19-0408.","journal-title":"Diabetes Care"},{"key":"3233_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/jcdd5030036","volume":"5","author":"E Hurt-Camejo","year":"2018","unstructured":"Hurt-Camejo E, Camejo G. ApoB-100 lipoprotein complex formation with intima proteoglycans as a cause of atherosclerosis and its possible ex vivo evaluation as a disease biomarker. J Cardiovasc Dev Dis. 2018;5:36. https:\/\/doi.org\/10.3390\/jcdd5030036.","journal-title":"J Cardiovasc Dev Dis"},{"key":"3233_CR29","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","volume":"15","author":"A Ajoolabady","year":"2024","unstructured":"Ajoolabady A, Pratico D, Lin L, Mantzoros CS, Bahijri S, Tuomilehto J, et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis. 2024;15:817. https:\/\/doi.org\/10.1038\/s41419-024-07166-8.","journal-title":"Cell Death Dis"},{"key":"3233_CR30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacl.2025.05.024","volume":"19","author":"D Sehayek","year":"2025","unstructured":"Sehayek D, Cole J, Bj\u00f6rnson E, Wilkins JT, Mortensen MB, Dufresne L, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. J Clin Lipidol. 2025;19:844\u201359. https:\/\/doi.org\/10.1016\/j.jacl.2025.05.024.","journal-title":"J Clin Lipidol"},{"key":"3233_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014400","volume":"98","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Du S, Shen S, Luo P, Ding S, Wang G, et al. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia. Medicine (Baltimore). 2019;98:e14400. https:\/\/doi.org\/10.1097\/MD.0000000000014400.","journal-title":"Medicine (Baltimore)"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03233-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:31:40Z","timestamp":1787095900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03233-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3233"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03233-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0\u0300 Cattolica del Sacro Cuore, Roma, Italy. Informed consent was obtained from all subjects involved in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read the document and agree to its publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Andrea Flex is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for data integrity and data analysis accuracy.","order":3,"name":"Ethics","label":"Guarantor's statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"241"}}